| Literature DB >> 28605636 |
Charles J Russell1, Bart G Jones2, Robert E Sealy2, Sherri L Surman2, John N Mason2, Randall T Hayden3, Ralph A Tripp4, Toru Takimoto5, Julia L Hurwitz6.
Abstract
Human metapneumovirus (hMPV) infections pose a serious health risk to young children, particularly in cases of premature birth. No licensed vaccine exists and there is no standard treatment for hMPV infections apart from supportive hospital care. We describe the production of a Sendai virus (SeV) recombinant that carries a gene for a truncated hMPV fusion (F) protein (SeV-MPV-Ft). The vaccine induces binding and neutralizing antibody responses toward hMPV and protection against challenge with hMPV in a cotton rat system. Results encourage advanced development of SeV-MPV-Ft to prevent the morbidity and mortality caused by hMPV infections in young children.Entities:
Keywords: Immunity; Metapneumovirus; Neutralizing antibodies; Recombinant vaccine; Respiratory virus; Sendai virus
Mesh:
Substances:
Year: 2017 PMID: 28605636 PMCID: PMC5551427 DOI: 10.1016/j.virol.2017.05.021
Source DB: PubMed Journal: Virology ISSN: 0042-6822 Impact factor: 3.616